Russia urged to open up its pharmaceuticals market to Indian imports

4 July 2012

Russia should open its booming $19 billion pharmaceuticals market and expedite the list of 500 drugs that it currently imports from India, said India’s Commerce, Industry and Textiles Minister Anand Sharma during a recent visit to St Petersburg, urging Russian authorities to let Indian pharmaceutical companies form joint partnerships with Russian companies, reports the Indian Business Standard newspaper.

India has asked Russia to establish a nodal agency to create a joint committee for implementation of memorandum of understanding between Indian and Russian pharma companies, especially in the field of quality control and standard requirements on conformity assessment of pharmaceuticals and bio-pharmaceuticals. India has already nominated its own nodal agency - The National Institute of Pharmaceutical Education and Research (NIPER) - under the Department of Pharmaceuticals.

Barriers to access $19 billion market

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics